Organisation paid for research Program year 2025 Source: CMS Open Payments

Altus Research

Neither a doctor nor a teaching hospital

Research payments

$1,856,724

216 payments

Through program year 2025, Altus Research is reported as receiving $1,856,724 in research payments, across 216 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$444,500	67
2024	Research	$182,178	10
2023	Research	$377,212	15
2022	Research	$19,356	19
2021	Research	$66,765	34
2020	Research	$193,904	32
2019	Research	$572,810	39

Breakdown

Who paid Research payments · program years 2019–2025

Ventana Medical Systems, Inc. $566,914 22 payments
Roche Molecular Systems, Inc. $393,831 59 payments
Gen-Probe, Inc. $336,148 9 payments
Eli Lilly and Company $152,844 1 payment
Exeltis, USA Inc. $108,819 49 payments
AstraZeneca Pharmaceuticals LP $48,948 2 payments
Sebela Pharmaceuticals Inc. $44,945 8 payments
GlaxoSmithKline, LLC. $43,630 7 payments
AMAG Pharmaceuticals, Inc. $36,786 7 payments
Pfizer Inc. $32,074 19 payments

Studies the money was for Research payments · program years 2019–2025

Rd003109 $566,914 22 payments
A10940-SC2/FluP-CSP-02 $333,158 8 payments
Rd007113 $286,627 28 payments
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Intravenous Bimagrumab, Alone Or in Addition to Open Label Subcutaneous Semaglutide, to Investigate the Efficacy and Safety in Overweight Or Obese Men and Women $152,844 1 payment
Rd006866 $67,460 20 payments
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $48,948 2 payments
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles $45,984 22 payments
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women $41,065 6 payments
Rd007312 $39,657 9 payments
A Phase 3, Prospective, Multi-Center, Single-Arm, Open-Label Study to Evaluate VeraCept, a Long-Acting Reversible Intrauterine Contraceptive for Contraceptive Efficacy, Safety, and Tolerability $38,945 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.